Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Roberta A Glynn"'
Autor:
Candice Horn, Martin Pass, James W. Janetka, Kevin Daly, Nicholas John Newcombe, Mei Su, Stephanie Springer, Stephanos Ioannidis, Paul Lyne, Patrick Brassil, Melissa Vasbinder, Dingwei Yu, Vibha Oza, Chun Deng, Lynsie Almeida, Dorin Toader, Sonya Zabludoff, Susan Ashwell, Yan Yu, Roberta E. Glynn, Thomas Gero
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:4242-4248
Checkpoint kinase-1 (Chk1, CHEK1) is a Ser/Thr protein kinase that mediates the cellular response to DNA-damage. A novel class of 2-ureido thiophene carboxamide urea (TCU) Chk1 inhibitors is described. Inhibitors in this chemotype were optimized for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee6ec0ff20c8d92f14796e23b64b1fda
https://doi.org/10.1016/j.bmcl.2008.05.016
https://doi.org/10.1016/j.bmcl.2008.05.016
Autor:
Jay R. Luly, Kenneth G. Carson, David J Heilig, Wen Song Yue, Shixin Qin, Jie Jack Li, David T. Connor, Joseph Edwin Low, Roberta A Glynn, Bharat K. Trivedi, Qing Ye, Stephen W. Hunt, Steven R. Miller, Bruce D. Roth, Weixing Yang
Publikováno v:
Bioorganic & Medicinal Chemistry. 11:3777-3790
Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e74b9b8847daee0af115d942196a4b
https://doi.org/10.1016/s0968-0896(03)00399-7
https://doi.org/10.1016/s0968-0896(03)00399-7
Autor:
Laura L. Poling, Peter U. Park, Venu R. Gurijala, Mao Yin, Dennis McGillicuddy, Cheri A. Stevenson, Joshua D. Thomas, Timothy B. Lowinger, Michael J. DeVit, Natalya D. Bodyak, Alex Uttard, LiuLiang Qin, Roberta E. Glynn, Elena Ter-Ovaneysan, Alex Yurkovetskiy, Dmitry R. Gumerov, Patrick R. Conlon
Publikováno v:
Cancer Research. 74:2645-2645
The application of biodegradable polymers to antibody-drug conjugate (ADC) design can provide numerous advantages, including significantly higher drug-antibody ratios, the use of alternative payloads with potencies considered insufficient for direct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9e02998836a38d4f952695de6d2df2f
https://doi.org/10.1158/1538-7445.am2014-2645
https://doi.org/10.1158/1538-7445.am2014-2645